Fluorouracil and Dose-Dense Chemotherapy in Adjuvant Treatment of Patient with Early-Stage Breast Cancer: an Open-Label, 2 x 2 Factorial, Randomised Phase III Trial

被引：0
|
作者：
Colle, E. [1 ]
Besse, B. [2 ]
机构：
[1] AERIO, Paris, France
[2] Gustave Roussy, F-94800 Villejuif, France
来源：
ONCOLOGIE | 2015年 / 17卷 / 7-8期
关键词：
METAANALYSIS;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：330 / 332
页数：3
相关论文
共 50 条
  • [41] Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial
    Goss, Paul E.
    Smith, Ian E.
    O'Shaughnessy, Joyce
    Ejlertsen, Bent
    Kaufmann, Manfred
    Boyle, Frances
    Buzdar, Aman U.
    Fumoleau, Pierre
    Gradishar, William
    Martin, Miguel
    Moy, Beverly
    Piccart-Gebhart, Martine
    Pritchard, Kathleen I.
    Lindquist, Deborah
    Chavarri-Guerra, Yanin
    Aktan, Gursel
    Rappold, Erica
    Williams, Lisa S.
    Finkelstein, Dianne M.
    LANCET ONCOLOGY, 2013, 14 (01): : 88 - 96
  • [42] Phase 2 feasibility study of dose-dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate with or without prophylactic growth factor (GF) for adjuvant treatment of early-stage breast cancer (EBC)
    Traina, Tiffany A.
    Kaufman, Peter Andrew
    Cadoo, Karen Anne
    Hudis, Clifford A.
    Chang, Cassandra
    Berrak, Erhan
    Song, James
    Cox, David
    Seidman, Andrew David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Management of febrile neutropenia in a breast cancer patient with SARS-CoV-2 infection during dose-dense adjuvant chemotherapy
    Abed, Zahraa Kadhim
    Mohammed, Zainab Hussein
    JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY, 2023, 30 (09): : E383 - E388
  • [44] Management of febrile neutropenia in a breast cancer patient with SARS-CoV-2 infection during dose-dense adjuvant chemotherapy
    Terebinska, Joanna
    Wojciechowski, Robert
    Zielinski, Filip
    Skrzypczyk-Ostaszewicz, Anna
    Zegadlo, Arkadiusz
    Lisiak, Emil
    Maliborski, Artur
    Duchnowska, Renata
    ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (02): : 131 - 132
  • [45] Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies
    Lambertini, Matteo
    Ceppi, Marcello
    Cognetti, Francesco
    Cavazzini, Giovanna
    De Laurentiis, Michele
    De Placido, Sabino
    Michelotti, Andrea
    Bisagni, Giancarlo
    Durando, Antonio
    Valle, Enrichetta
    Scotto, Tiziana
    De Censi, Andrea
    Turletti, Anna
    Benasso, Marco
    Barni, Sandro
    Montemurro, Filippo
    Puglisi, Fabio
    Levaggi, Alessia
    Giraudi, Sara
    Bighin, Claudia
    Bruzzi, Paolo
    Del Mastro, Lucia
    EUROPEAN JOURNAL OF CANCER, 2017, 71 : 34 - 42
  • [46] Phase II open-label trial investigating percutaneous laser ablation for treatment of early-stage breast cancer: MRI, pathology, and outcome correlations
    Schwartzberg, Barbara
    Lewin, John
    Abeldelatif, Osama
    Bernard, Jacqueline
    Bu-Ali, Hanadi
    Cawthorn, Simon
    Chen-Seetoo, Margaret
    Feldman, Sheldon
    Govindarajulu, Sasirekha
    Jones, Lyn
    Juette, Arne
    Kavia, Sanjay
    Maganini, Robert
    Pain, Simon
    Shere, Mike
    Shriver, Craig
    Smith, Simon
    Valencia, Alexandra
    Whitacre, Eric
    Whitney, Roger
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : 283 - 284
  • [47] Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
    Katsumata, Noriyuki
    Yasuda, Makoto
    Takahashi, Fumiaki
    Isonishi, Seiji
    Jobo, Toshiko
    Aoki, Doisuke
    Tsuda, Hiroshi
    Sugiyama, Toru
    Kodama, Shoji
    Kimura, Eizo
    Ochiai, Kazunori
    Noda, Kiichiro
    LANCET, 2009, 374 (9698): : 1331 - 1338
  • [48] Phase I/II feasibility trial of adjuvant dose-dense (DD) docetaxel/epirubicin/cyclophosphamide (TEC) in stage II/III breast cancer.
    Burdette-Radoux, S
    Wood, ME
    Olin, JJ
    Broom, R
    Crocker, A
    Ashikaga, T
    Muss, HB
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 81S - 81S
  • [49] Phase I lead-in to a 2x2x2 factorial trial of dose-dense temozolomide, memantine, mefloquine, and metformin as postradiation adjuvant therapy of glioblastoma (GBM).
    Penas-Prado, Marta
    Groves, Morris D.
    Mammoser, Aaron A.
    Melguizo, Isaac
    De Groot, John Frederick
    Conrad, Charles A.
    Tremont-Lukats, Ivo
    Loghin, Monica Elena
    Puduvalli, Vinay K.
    Sulman, Erik P.
    Hess, Kenneth R.
    Aldape, Kenneth D.
    Gilbert, Mark R.
    Yung, W. K. Alfred
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
    Seymour, Matthew T.
    Thompson, Lindsay C.
    Wasan, Harpreet S.
    Middleton, Gary
    Brewster, Alison E.
    Shepherd, Stephen F.
    O'Mahony, M. Sinend
    Maughan, Timothy S.
    Parmar, Mahesh
    Langley, Ruth E.
    LANCET, 2011, 377 (9779): : 1749 - 1759
12345